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Irving Weissman: ISSCR’s President-ElectIrving Weissman, the incoming president
of the International Society for Stem Cell
Research (ISSCR), promises not to shy
away from speaking his mind during his
term.His goal to serve asa vocal advocate
for the society should come as no sur-
prise, given that he has been outspoken
throughout his 50+ years in the stem cell
field.
Weissmanwasnoordinary teenager. As
a high-school student of just 16, he began
his scientific career when he spent a
summer helping out in the laboratory of
renowned pathologist Ernst Eichwald at
what was then the Montana Deaconess
Hospital in Great Falls, Montana. He liked
it somuch, heworked after school and the
following summer, and when he gradu-
ated from high school in 1957, he already
had two scientific papers to his name.
Others soon followed, so that by the time
he’d completed his premedical studies
at Montana State University in 1961, he
could boast a string of publications. It
was this track record rather than any
academic accolades that won Weissman
a place at Stanford School of Medicine.
‘‘At no stage in my career did I ever get
into the top 10% of my class by grades,’’
he says. ‘‘The only reason I got admitted
to Stanford was the papers I’d written.’’
Weissman picks out one in particular
that pointed him toward the stemcell field.
In 1955, Eichwald and a colleague had
found that skin grafts performed between
inbred mice were mostly accepted by the
recipient, but not if the donor was male
and the host female. It was the first clear
evidence of a male-specific antigen, and
Weissman set out to see if he could induce
tolerance of male-to-female transplants
in these mice. Inspired by the pioneering
work of Rupert Billingham, Leslie Brent,
and Peter Medawar on transplantation
immunity, Weissman transplanted bone
marrow and spleen cells from males into
newborn or immunosuppressed females,
making their immune systems accept all
subsequent grafts from the donor male.
‘‘It made me wonder what it was in bone
marrow that could persist for the life of
the host,’’ he says. ‘‘It was this experiment
that really hooked me into science.’’
This result opened up therapeutic
opportunities that were immediatelyobvious to Weissman. Over lunch with
his mother, he made the bold prediction
that within 5 years patients would be
receiving bone marrow on a routine
basis, preparing the immune system of
an adult to receive a transplant of virtually
any tissue from any unrelated individual.
‘‘What I didn’t reckon on was how hard it
is to move things from science to medi-
cine,’’ he says.
It’s not for want of trying. After the first
clear evidence that stem cells are present
in mouse bone marrow was reported,
Weissman spent 9 invaluable months in
Jim Gowans’ laboratory at Oxford Univer-
sity in the UK. His express mission was
to find out more about the role of the
thymus in the maturation of T cells from
bone marrow cells. ‘‘Gowans’ approach
to discover that lymphocytes were the
specific cells of the immune system was
to purify, purify, purify,’’ says Weissman.
He was able to purify lymphocytes from
the thoracic duct, label them, and return
them to live rats to discover where they
went and what they did.
In time, Weissman’s obsession with
purification and in vivo verification led
to several publications of major conse-
quence for the stem cell field. In July
1988, he and his colleagues became the
first to purify mouse hematopoietic stem
cells and demonstrate their multipotent
properties (something he would repeat
in humans in 1992). ‘‘We showed that
transplanting blood-forming stem cells to
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all blood cell types and save the lives of all
the animals,’’ says Weissman.
The next logical step was to find a way
to study analogous human stem cells in
an animal system, ultimately with a view
to rolling stem cell therapy out into clinical
trials. Also in 1988, Weissman, Michael
McCune, and colleagues generated a
model of the human immune system by
transplanting human fetal blood-forming
and lymphocyte-forming organs into
severe combined immunodeficient (SCID)
mice.
Weissman had a lot planned for those
early SCID-human (SCID-hu) chimeric
mice, includingstudyingHIV-infectedcells
of the human immune system in vivo and
testing the efficacy of drugs to combat
the virus. But getting the funding for such
edgy experiments proved harder than
he had imagined. Enter Systemix, which
Weissman cofounded with McCune and
New York venture capitalist Eli Jacobs to
realize the promise of the SCID-humouse.
With plenty of funds and the freedom to
carry out the experiments, things began
well.
When the Swiss drug and chemical
giant Sandoz Ltd bought a hefty stake in
Systemix in 1992, the future looked even
brighter. ‘‘I thought that a lot of our prob-
lems were over because Sandoz was
committed to a lot of the same things,’’
says Weissman. ‘‘But what I didn’t reckon
on was that leadership changes in the
pharmaceutical industry and the people
whosaw this as something that youshould
rush to make real in humans were gone
withinayearof thesaleandwehadawhole
new group of executives to deal with.’’
Although this turnover slowed down the
research, in 1996 Sandoz began three
clinical trials involving stem cells, with the
goal of improving the survival of cancer
patients by regenerating their blood-form-
ing systems with cancer-free stem cells
after high-dose chemotherapy. ‘‘At last
we were going to do human stem cell
transplants. We had a chance we were
going to improve the therapy. We had
a company backing us, with the money
in place to do it.’’
But within months of starting the trials,
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Ciba-Geigy to form Novartis. ‘‘Their goals
were not the same as ours, so even before
the results of those three clinical trials
started coming out, they decided they
weren’t going to back this work any
further,’’ says Weissman. Worse still,
Novartis held all the patents necessary
for taking the research forward, either
licensed to them from Stanford University
or invented at Systemix or Sandoz. In the
meantime, the transplant team at Stan-
ford, led by Robert Negrin, was beginning
to see the benefits of receiving purified
stem cell transplants after high-dose
chemotherapy. ‘‘At three years in the
stage IV breast cancer patients, instead
of 6% alive without disease from a similar
study using unpurified mobilized periph-
eral blood (MPB), the patient group
receiving breast cancer-free stem cells
was 45% alive without disease,’’ says
Weissman.
He had another shot at developing stem
cell therapies within the commercial
sector, this time at California-based
Cellerant Therapeutics. But he experi-
enced only further frustration: ‘‘I have
now resigned as a director, sold off all478 Cell Stem Cell 4, June 5, 2009 ª2009 Elmy shares, and removed any consulting
activities I have with them on stem cells.’’
The patents too have nearly come full
circle. ‘‘We are engaged in negotiations
to bring the know-how and the isolating
antibodies back to Stanford University
and the California Institute of Regenera-
tiveMedicine,’’ he says. These institutions
may fund key clinical trials that he hopes
will act as proof of the therapeutic prin-
ciple, finally pushing stem cells into the
medical mainstream and giving compa-
nies the confidence to take on the devel-
opment of stem cell products.
There are other reasons for being
upbeat. After a decade of tireless advo-
cacy of stem cell research during the
Bush era, Weissman is clearly delighted
at the tone set by the new US administra-
tion and the funds that are beginning to
flow toward stem cell research. But as
the new president of the ISSCR, he is
likely to be as outspoken as ever in favor
of further reform. In particular, he is critical
of current NIH guidelines to fund research
into cell lines developed by the iPSC
method but not those developed by
nuclear transfer. ‘‘It sounds like they
have taken the stance that this is a worthysevier Inc.gamble’’ he says. ‘‘I don’t want to gamble
when patients’ lives could be the stake.’’
Weissman is also likely to use his presi-
dency to go on the offensive against those
using the potential of stem cells to sell un-
verified treatments. Of particular concern
are those cases where cells are being
given to patients with only faint prospects
of stimulating local blood vessel activa-
tion, let alone regenerating entire tissues.
Worse still, says Weissman, are those
using the promise of stem cells to prey
on the vulnerability of patients with incur-
able diseases. ‘‘If I have my way, we
will look at the entire spectrum of these
abuses and, like the American Cancer
Society, investigate and list groups that
use unproven stem cell therapies,’’ he
says.
It’s been a longer journey than Weiss-
man ever imagined. ‘‘It just makes me
realize how naive I was when I sat down
with my mom and said this is going to
happen in the next 5 years. It’s 50 years
later.’’ Now at the age of 69, will he live
to see the day when his teenaged fantasy
becomes a reality and stem cell therapies
have become routine? ‘‘You betcha,’’ he
says.
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